Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 May 1;72(9):2197-205.
doi: 10.1158/0008-5472.CAN-11-3909.

Epigenetic resensitization to platinum in ovarian cancer

Daniela Matei  1 , Fang Fang, Changyu Shen, Jeanne Schilder, Alesha Arnold, Yan Zeng, William A Berry, Tim Huang, Kenneth P Nephew
Affiliations
Clinical Trial

Epigenetic resensitization to platinum in ovarian cancer

Daniela Matei et al. Cancer Res. .

Abstract

Preclinical studies have shown that hypomethylating agents reverse platinum resistance in ovarian cancer. In this phase II clinical trial, based upon the results of our phase I dose defining study, we tested the clinical and biologic activity of low-dose decitabine administered before carboplatin in platinum-resistant ovarian cancer patients. Among 17 patients with heavily pretreated and platinum-resistant ovarian cancer, the regimen induced a 35% objective response rate (RR) and progression-free survival (PFS) of 10.2 months, with nine patients (53%) free of progression at 6 months. Global and gene-specific DNA demethylation was achieved in peripheral blood mononuclear cells and tumors. The number of demethylated genes was greater (P < 0.05) in tumor biopsies from patients with PFS more than 6 versus less than 6 months (311 vs. 244 genes). Pathways enriched at baseline in tumors from patients with PFS more than 6 months included cytokine-cytokine receptor interactions, drug transporters, and mitogen-activated protein kinase, toll-like receptor and Jak-STAT signaling pathways, whereas those enriched in demethylated genes after decitabine treatment included pathways involved in cancer, Wnt signaling, and apoptosis (P < 0.01). Demethylation of MLH1, RASSF1A, HOXA10, and HOXA11 in tumors positively correlated with PFS (P < 0.05). Together, the results of this study suggest that low-dose decitabine altered DNA methylation of genes and cancer pathways, restoring sensitivity to carboplatin in patients with heavily pretreated ovarian cancer and resulting in a high RR and prolonged PFS.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Potential Conflicts of Interest

D. Matei and K.P. Nephew are consultants and on the advisory board of Supergen (now Astex Pharmaceuticals, Inc.).

Figures

Figure 1
Figure 1
Clinical activity. A, waterfall plot of RECIST defined responses (n = 16 patients with measurable disease). B, Kaplan–Meier curve for PFS. The solid line represents the estimation of the survival function and the dashed lines represent the 95% CIs.
Figure 2
Figure 2
Pharmacodynamic activity of decitabine on global DNA demethylation. A, LINE1 methylation measured by pyrosequencing in PBMCs on days 1 and 8 (C1D1, C1D8) of cycles 1 and 2 (C2D1, C2D8), and at end of study. Significant demethylation was found on C1D8 and C2D8 during the treatment. There was no difference between days 1 of both cycles. Bars/error bars represent mean ± SD. *, P < 0.05. B, LINE1 in biopsy samples from patients on days 1 and 8 of cycle 1. Bars/error bars represent mean ± SD. C, Venn diagrams show the numbers of demethylated and remaining hypermethylated genes in PBMCs after decitabine treatment in patients PFS less than 6 months versus PFS more than 6 months. Dotted line divides the demethylated gene numbers and remained hypermethylated gene numbers after first cycle treatment (β value greater than 0.5 is considered as hypermethylated). D, Venn diagrams show the numbers of demethylated genes and remaining hypermethylated genes in biopsies after decitabine treatment in patients achieving PFS less than 6 months versus PFS more than 6 months.
Figure 3
Figure 3
Differentially hypermethylated genes at baseline for PFS > 6 months versus PFS < 6 months. A, heat map represents the differences in gene methylation levels at baseline (i.e., pretreatment) in tumor biopsies (n = 14). Methylation levels are color coded as red (high β value) to green (low β value). P values less than 0.01, using 2-sample t tests comparing responders to nonresponders, were used for selecting differentially methylated genes. B, a map of enriched functional clusters based on functional clustering, using the online webtool DAVID, for genes that were hypermethylated in biopsies from responders (PFS > 6 months) versus nonresponders (PFS < 6 months), respectively. The size of the bars (wheel spokes) and the circles represent the gene counts and enrichment scores, respectively. Hypermethylation was defined by β values greater than 0.5 for all patients in the same PFS group. See Supplementary Table S3 for lists of specific gene members of each cluster group and enrichment scores. C, the pathways enriched for unique hypermethylated genes in PFS more than 6 months versus PFS less than 6 months, using the online gene functional analysis tool Pathway Express.
Figure 4
Figure 4
Specific ovarian cancer gene methylation levels. A, MLH1, showing plasma DNA demethylation after cycle 2, day 8 (C2D8); B, RASSF1A, similarly demethylated after C2D8; C, AKT1S1, demethylated after cycles 1, day 8 (C1D8), and 2, days 1 (C2D1) and 8 (C2D8), as measured by pyrosequencing on those specific cycles/days, and at end of study. D, baseline (pretreatment) methylation levels of HOXA10 in tumors or ascites, correlates with extended PFS. E, treatment-induced reduction of HOXA10 methylation levels in tumor biopsies, as correlated with patient PFS more than 6 months, versus patient PFS less than 6 months (P < 0.05). In A, B, C, and E, bars/error bars represent mean ± SD. *, P < 0.05.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bukowski RM, Ozols RF, Markman M. The management of recurrent ovarian cancer. Semin Oncol. 2007;34:S1–15. - PubMed
    1. Sandercock J, Parmar MK, Torri V, Qian W. First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br J Cancer. 2002;87:815–24. - PMC - PubMed
    1. Wei SH, Chen CM, Strathdee G, Harnsomburana J, Shyu CR, Rahmatpanah F, et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res. 2002;8:2246–52. - PubMed
    1. Barton CA, Hacker NF, Clark SJ, O’Brien PM. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol Oncol. 2008;109:129–39. - PubMed
    1. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128:683–92. - PMC - PubMed

Publication types

MeSH terms